{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:30:51Z","timestamp":1786606251374,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"DOI":"10.7759\/cureus.114452","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:13:07Z","timestamp":1786605187000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum N-terminal Pro-B-Type Natriuretic Peptide and Phosphodiesterase 4D Levels in Adults With Overt Hypothyroidism: A Case-Control Study"],"prefix":"10.7759","author":[{"given":"Syed Hasan","family":"Amir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khwaja Saifullah","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheelu","family":"Shafiq Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.174","article-title":"Thyroid hormones and cardiovascular disease","volume":"14","author":"Jabbar A","year":"2017","unstructured":"Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2017, 14:39-55. 10.1038\/nrcardio.2016.174","journal-title":"Nat Rev Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-02982-4","article-title":"Thyroid disorders and cardiovascular manifestations: an update","volume":"75","author":"Paschou SA","year":"2022","unstructured":"Paschou SA, Bletsa E, Stampouloglou PK, et al.. Thyroid disorders and cardiovascular manifestations: an update. Endocrine. 2022, 75:672-83. 10.1007\/s12020-022-02982-4","journal-title":"Endocrine"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-13-2-55","article-title":"Hypothyroidism and the heart","volume":"13","author":"Udovcic M","year":"2017","unstructured":"Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist Debakey Cardiovasc J. 2017, 13:55-9. 10.14797\/mdcj-13-2-55","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5830\/CVJA-2013-055","article-title":"Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP)","volume":"24","author":"Maries L","year":"2013","unstructured":"Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr. 2013, 24:286-9. 10.5830\/CVJA-2013-055","journal-title":"Cardiovasc J Afr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2003.12.015","article-title":"Essential biochemistry and physiology of (NT-pro)BNP","volume":"6","author":"Hall C","year":"2004","unstructured":"Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004, 6:257-60. 10.1016\/j.ejheart.2003.12.015","journal-title":"Eur J Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081820","article-title":"BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine","volume":"20","author":"Cao Z","year":"2019","unstructured":"Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci. 2019, 20:1820. 10.3390\/ijms20081820","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(01)01269-4","article-title":"Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction","volume":"37","author":"Richards AM","year":"2001","unstructured":"Richards AM, Doughty R, Nicholls MG, et al.. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol. 2001, 37:1781-7. 10.1016\/s0735-1097(01)01269-4","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00729","article-title":"BNP as a new biomarker of cardiac thyroid hormone function","volume":"11","author":"Wang K","year":"2020","unstructured":"Wang K, Ojamaa K, Samuels A, et al.. BNP as a new biomarker of cardiac thyroid hormone function. Front Physiol. 2020, 11:729. 10.3389\/fphys.2020.00729","journal-title":"Front Physiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.01941.x","article-title":"N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states","volume":"60","author":"Schultz M","year":"2004","unstructured":"Schultz M, Faber J, Kistorp C, Jarl\u00f8v A, Pedersen F, Wiinberg N, Hildebrandt P. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf). 2004, 60:54-9. 10.1111\/j.1365-2265.2004.01941.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref10","article-title":"Plasma levels of NT-pro-brain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism","volume":"62","author":"Paku\u0142a D","year":"2011","unstructured":"Paku\u0142a D, Marek B, Kajdaniuk D, et al.. Plasma levels of NT-pro-brain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism. Endokrynol Pol. 2011, 62:523-8.","journal-title":"Endokrynol Pol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-06959-1","article-title":"Cardiac cyclic nucleotide phosphodiesterases: roles and therapeutic potential in heart failure","volume":"34","author":"Preedy ME","year":"2020","unstructured":"Preedy ME. Cardiac cyclic nucleotide phosphodiesterases: roles and therapeutic potential in heart failure. Cardiovasc Drugs Ther. 2020, 34:401-17. 10.1007\/s10557-020-06959-1","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042145","article-title":"Phosphodiesterases and compartmentation of cAMP and cGMP signaling in regulation of cardiac contractility in normal and failing hearts","volume":"23","author":"Calamera G","year":"2022","unstructured":"Calamera G, Moltzau LR, Levy FO, Andressen KW. Phosphodiesterases and compartmentation of cAMP and cGMP signaling in regulation of cardiac contractility in normal and failing hearts. Int J Mol Sci. 2022, 23:2145. 10.3390\/ijms23042145","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/odi.12275","article-title":"Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets","volume":"21","author":"Ahmad F","year":"2015","unstructured":"Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis. 2015, 21:e25-50. 10.1111\/odi.12275","journal-title":"Oral Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003266","article-title":"A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function","volume":"9","author":"Porcu E","year":"2013","unstructured":"Porcu E, Medici M, Pistis G, et al.. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet. 2013, 9:e1003266. 10.1371\/journal.pgen.1003266","journal-title":"PLoS Genet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101746","article-title":"The endocrine function of the heart: physiology and involvements of natriuretic peptides and cyclic nucleotide phosphodiesterases in heart failure","volume":"8","author":"Lugnier C","year":"2019","unstructured":"Lugnier C, Meyer A, Charloux A, Andr\u00e8s E, G\u00e9ny B, Talha S. The endocrine function of the heart: physiology and involvements of natriuretic peptides and cyclic nucleotide phosphodiesterases in heart failure. J Clin Med. 2019, 8:1746. 10.3390\/jcm8101746","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-022-00756-z","article-title":"Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure","volume":"20","author":"Kamel R","year":"2023","unstructured":"Kamel R, Leroy J, Vandecasteele G, Fischmeister R. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure. Nat Rev Cardiol. 2023, 20:90-108. 10.1038\/s41569-022-00756-z","journal-title":"Nat Rev Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor PN","year":"2018","unstructured":"Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018, 14:301-16. 10.1038\/nrendo.2018.18","journal-title":"Nat Rev Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.113755","article-title":"Prevalence of hypothyroidism in adults: an epidemiological study in eight cities of India","volume":"17","author":"Unnikrishnan AG","year":"2013","unstructured":"Unnikrishnan AG, Kalra S, Sahay RK, Bantwal G, John M, Tewari N. Prevalence of hypothyroidism in adults: an epidemiological study in eight cities of India. Indian J Endocrinol Metab. 2013, 17:647-52. 10.4103\/2230-8210.113755","journal-title":"Indian J Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1083171","article-title":"Effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide levels: a systematic review and meta-analysis","volume":"14","author":"Zhang H","year":"2023","unstructured":"Zhang H, Li X, Zhang N, Tian L. Effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide levels: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023, 14:1083171. 10.3389\/fendo.2023.1083171","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","article-title":"Analyses of brain natriuretic peptide levels in patients with newly diagnosed hyperthyroidism without cardiac diseases","volume":"17","author":"Idan AS","year":"2023","unstructured":"Idan AS, Hamzah MI, Khudhair MS. Analyses of brain natriuretic peptide levels in patients with newly diagnosed hyperthyroidism without cardiac diseases. Biochem Mosc Suppl B Biomed Chem. 2023, 17:92-100.","journal-title":"Biochem Mosc Suppl B Biomed Chem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/biology11071034","article-title":"B-type natriuretic peptide (BNP) revisited - is BNP still a biomarker for heart failure in the angiotensin receptor\/neprilysin inhibitor era?","volume":"11","author":"Nishikimi T","year":"2022","unstructured":"Nishikimi T, Nakagawa Y. B-type natriuretic peptide (BNP) revisited - is BNP still a biomarker for heart failure in the angiotensin receptor\/neprilysin inhibitor era?. Biology (Basel). 2022, 11:1034. 10.3390\/biology11071034","journal-title":"Biology (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020794","article-title":"Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach","volume":"25","author":"Stoicescu L","year":"2024","unstructured":"Stoicescu L, Cri\u015fan D, Morgovan C, Avram L, Ghibu S. Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. Int J Mol Sci. 2024, 25:794. 10.3390\/ijms25020794","journal-title":"Int J Mol Sci"},{"key":"ref23","article-title":"Is it the time to revolutionize the heart failure management with emerging biomarkers and innovative targeted treatments? From research evidence to clinic","volume":"26","author":"Asta L","year":"2025","unstructured":"Asta L, Pisano C, Sbrigata A, Raffa G, Scola L, Balistreri CR. Is it the time to revolutionize the heart failure management with emerging biomarkers and innovative targeted treatments? From research evidence to clinic. Int J Mol Sci. 2025, 26:1556.","journal-title":"Int J Mol Sci"},{"key":"ref24","article-title":"Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents","volume":"82","author":"Manganiello VC","year":"1999","unstructured":"Manganiello VC, Degerman E. Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb Haemost. 1999, 82:407-11.","journal-title":"Thromb Haemost"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/mend.14.9.0534","article-title":"Phosphodiesterases and cyclic nucleotide signaling in endocrine cells","volume":"14","author":"Conti M","year":"2000","unstructured":"Conti M. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Endocrinol. 2000, 14:1317-27. 10.1210\/mend.14.9.0534","journal-title":"Mol Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.036859","article-title":"Thyroid and cardiovascular disease: research agenda for enhancing knowledge, prevention, and treatment","volume":"139","author":"Cappola AR","year":"2019","unstructured":"Cappola AR, Desai AS, Medici M, et al.. Thyroid and cardiovascular disease: research agenda for enhancing knowledge, prevention, and treatment. Circulation. 2019, 139:2892-909. 10.1161\/CIRCULATIONAHA.118.036859","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae001","article-title":"Association of thyroid dysfunction in individuals \u2265 65 years of age with subclinical cardiac abnormalities","volume":"109","author":"Barasch E","year":"2024","unstructured":"Barasch E, Gottdiener J, Buzkova P, et al.. Association of thyroid dysfunction in individuals \u2265 65 years of age with subclinical cardiac abnormalities. J Clin Endocrinol Metab. 2024, 109:1847-56. 10.1210\/clinem\/dgae001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-017-0312-5","article-title":"Thyroid dysfunction and heart failure: mechanisms and associations","volume":"14","author":"Vargas-Uricoechea H","year":"2017","unstructured":"Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid dysfunction and heart failure: mechanisms and associations. Curr Heart Fail Rep. 2017, 14:48-58. 10.1007\/s11897-017-0312-5","journal-title":"Curr Heart Fail Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.183454","article-title":"Hypothyroidism and obesity: an intriguing link","volume":"20","author":"Sanyal D","year":"2016","unstructured":"Sanyal D, Raychaudhuri M. Hypothyroidism and obesity: an intriguing link. Indian J Endocrinol Metab. 2016, 20:554-7. 10.4103\/2230-8210.183454","journal-title":"Indian J Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0028","article-title":"Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile","volume":"6","author":"Abreu IM","year":"2017","unstructured":"Abreu IM, Lau E, de Sousa Pinto B, Carvalho D. Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile. Endocr Connect. 2017, 6:188-99. 10.1530\/EC-17-0028","journal-title":"Endocr Connect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516002-serum-n-terminal-pro-b-type-natriuretic-peptide-and-phosphodiesterase-4d-levels-in-adults-with-overt-hypothyroidism-a-case-control-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:13:09Z","timestamp":1786605189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516002-serum-n-terminal-pro-b-type-natriuretic-peptide-and-phosphodiesterase-4d-levels-in-adults-with-overt-hypothyroidism-a-case-control-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.114452","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}